Meeder Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Meeder Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-211	Closed	-$7K	–	859
2022 Q3	$7K	Hold	211	–	–	﹤0.01%	1441
2022 Q2	$7K	Sell	211 -2,074	-91%	-$72.5K	﹤0.01%	1491
2022 Q1	$105K	Buy	+2,285	New	+$109K	0.01%	783
2021 Q4	–	Sell	-2,084	Closed	-$156K	–	1210
2021 Q3	$156K	Buy	2,084 +10	+0.5%	+$839	0.01%	786
2021 Q2	$192K	Buy	2,074 +1,808	+680%	+$154K	0.01%	736
2021 Q1	$24K	Hold	266	–	–	﹤0.01%	1350
2020 Q4	$25K	Hold	266	–	–	0.01%	744
2020 Q3	$17K	Buy	+266	New	+$15.6K	﹤0.01%	1209

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Meeder Asset Management's ARKG Position: Q4 2022 in Review

Meeder Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 211 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in ARKG in Q3 2020 and held it in 8 quarters. The position peaked at $192K in Q2 2021. 321 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

Meeder Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 211 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $7K.
Meeder Asset Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 8 quarters.
Meeder Asset Management's ARK Genomic Revolution ETF position peaked at $192K in Q2 2021.
321 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.